Research synthesis only; not medical advice. This guide explains how peptide identity and product quality are established — and why neither can be read off a label or a database record. Nothing here authenticates any commercial product.
A chemical name is not a chemical identity. In the peptide market, the gap between the two is where most confusion — and most risk — lives. This guide explains the gap in plain language.
The same name can mean different molecules
Market names are marketing, not chemistry. Documented examples from this atlas:
"CJC-1295" is used by most vendors to mean Modified GRF 1-29 — a substance with no drug-affinity-complex conjugate — which is chemically different from the CJC-1295 DAC conjugate that has published human pharmacology data. The CJC-1295 monograph and Modified GRF (1-29) monograph keep the boundary explicit.
"TB-500" may mean full-length thymosin beta-4 or a short 7-amino-acid fragment — different molecules with different evidence. See TB-500 and thymosin beta-4.
Semax and Selank listings may use the parent peptide or an acetylated/amidated variant interchangeably — compare Semax with N-Acetyl Semax Amidate.
Why it matters: evidence attaches to the studied molecule, not the market name. A trial of one variant says nothing about another, and the atlas refuses to transfer claims across the boundary.
Salts, fragments, conjugates, and mixtures
Even with an honest seller, "the peptide" is often not a single neutral molecule:
Salts — many peptides are handled as acetate or hydrochloride salts. The active sequence is the same, but the salt form is part of the product's composition.
Fatty-acid conjugates — semaglutide carries a C18 fatty-diacid chain and liraglutide a C16 palmitoyl chain; these attachments are integral to how the drugs work, not optional extras.
Metal complexes — GHK-Cu is a copper complex, and even its database records are ambiguous: the PubChem record (CID 133697840) represents a 2:1 bis(GHK)-copper species, not necessarily the 1:1 complex the market name usually intends.
Mixtures — thymalin and cerebrolysin are undefined peptide mixtures from tissue extracts; no single sequence applies.
Random copolymers — glatiramer acetate has no defined sequence at all.
The full taxonomy, with per-entry decisions, is in How Peptide Identity and Structure Assets Are Verified and the blog explainer How Peptide Identity Is Verified.
What database identifiers actually prove
Monographs list stable identifiers: The record number of a compound in PubChem, the atlas's primary structure-asset source. A registry record or depiction does not authenticate a commercial sample. Definition source: Identity and structure assets methodology · Glossary, CAS number, FDA UNII, DrugBank ID. Each answers a narrow question:
| Identifier | What it establishes | What it does not establish |
|---|---|---|
| PubChem CID | A registry record with a structural definition, retrievable by anyone | That any physical sample matches the record |
| DrugBank ID | Pharmacological identity and sequence for a known drug | That differently marketed material is the same product |
| FDA UNII | A unique ingredient identifier used in FDA substance records | Approval, quality, or sample authenticity |
| CAS number | A chemical registry assignment | Purity or provenance of any batch |
Read every identifier as a pointer to a registry entry, nothing more. Registry identity and sample authenticity are different questions; answering the second takes laboratory work, not a database lookup.
How to read a peptide's structure
The sequence is the primary structure — the order of amino-acid residues. For small peptides (under roughly 40 residues), PubChem usually stores a defined chemical structure.
2D depictions are renderings, not photographs. The atlas draws them locally from PubChem SMILES. A flat image cannot show the three-dimensional fold, and disulfide bridges (as in oxytocin, ziconotide, and linaclotide) appear as S—S bonds without spatial arrangement. Cyclic peptides like cyclosporine are drawn as planar cycles, not macrocyclic folds.
Stereochemistry is load-bearing. Many peptides contain D-amino acids — D-Phe, D-Trp, D-Arg appear in octreotide, ipamorelin, and cetrorelix — and swapping one changes activity. A depiction with assigned wedge/hash bonds is still a flattened drawing, not an analytically determined structure.
Some entries get no image at all. Large or modified proteins — dulaglutide, mecasermin, follistatin-344 — have no stable small-molecule depiction, and the atlas marks that explicitly rather than inventing one.
When authoritative evidence cannot resolve a unique entity, the atlas keeps the ambiguity visible instead of forcing a structure. The boundary-case table on the identity methodology page lists these explicitly.
Product quality: sterility, purity, authenticity
Identity on paper is only the first layer. For any physical product, quality is multidimensional — and each dimension needs its own suitable test:
Identity and assay — is it the stated peptide, and how much is present?
Purity — what related substances, degradation products, or process impurities come along?
Sterility and endotoxins — for anything injectable, microbial and pyrogen control comes from a validated manufacturing system; a sampled lab test is only one part of that assurance.
Content uniformity, particulates, pH, container integrity — each measured separately, each with its own method and acceptance criteria.
Three rules of thumb follow:
Passing one attribute proves nothing about the others. A purity chromatogram does not establish identity, sterility, or endotoxin control.
A result applies to the sampled material, method, and moment in time — not automatically to other vials, lots, or vendors. Vendor certificates of analysis are select-sample reports with method and chain-of-custody limits.
Appearance is not evidence. Visual inspection cannot reveal degradation, amount discrepancies, sterility failure, or endotoxin contamination.
The detailed treatment — compendial methods, counterfeit detection, packaging — is in Product quality, authenticity, and testing and Sterility, asepsis, and contamination risk.
Where to go next
How to Read a Peptide Monograph — find the identity table and caveats in any entry
Peptide Safety Fundamentals — why quality gaps become safety gaps
Understanding Peptide Regulation — why unapproved material has no quality oversight
Best-Known Peptide Stack Profiles — identity ambiguity inside multi-peptide blends
Administration science overview — Freeze-drying: water is removed by sublimation under reduced pressure, which can improve the stability of peptides and yield a porous dry matrix. Water removal does not sterilize a product, prove its quality, or define how it should later be handled. Definition source: Lyophilization, formulation, and stability primer · Glossary, storage, and stability concepts
Glossary — definitions of identity and quality terms
Sources
Peptides Community — How Peptide Identity and Structure Assets Are Verified
Peptides Community — Product quality, authenticity, and testing
Peptides Community — Sterility, asepsis, and contamination risk
Peptides Community — TB-500 monograph
Peptides Community — GHK-Cu monograph